ReviewThe Journal of infectious diseases2018
Can Biomarkers Advance HIV Research and Care in the Antiretroviral Therapy Era?
Review in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Effects of Korean red ginseng on the HIV-1Journal of ginseng research · 2026Article
- Biomarkers of microbial translocation and generalized inflammation are associated with frailty among people with HIV.AIDS (London, England) · 2025Article
- Systemic Inflammation and Gastrointestinal Complications in HIV Patients: A Cross-Sectional Study on the Role of Type II Diabetes.Pathogens (Basel, Switzerland) · 2025Article
- Cardiovascular Implications of Immune Disorders in Women.Circulation research · 2022 · on this mapReview
- Menopause Is Associated With Immune Activation in Women With HIV.The Journal of infectious diseases · 2022Article
- HIV-Associated Cancer Biomarkers: A Requirement for Early Diagnosis.International journal of molecular sciences · 2021Review
- Evolution of Serum Acute-Phase Glycoproteins Assessed byFrontiers in immunology · 2021Article
- Salivary biomarkers associated with the progression of disease in people living with HIV: A scoping review protocol.F1000Research · 2021Article
- Beyond the HIV Care Continuum and Viral Suppression: Broadening the Scope of Quality Metrics for Total HIV Patient Care.AIDS patient care and STDs · 2020Article
- Mining for humoral correlates of HIV control and latent reservoir size.PLoS pathogens · 2020Article
- Interferon gamma-induced protein 10 (IP-10) and cardiovascular disease in African Americans.PloS one · 2020Observational
- Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop.Pathogens & immunity · 2020Article
- Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and HIV/HCV Coinfection.Open forum infectious diseases · 2019Article
- Biomarkers of aging in HIV: inflammation and the microbiome.European geriatric medicine · 2019Review
- Plasma glycomics predict cardiovascular disease in patients with ART-controlled HIV infections.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite achieving human immunodeficiency virus type 1 (HIV-1) RNA suppression below levels of detection and, for most, improved CD4+ T-cell counts, those aging with HIV experience excess low-level inflammation, hypercoagulability, and immune dysfunction (chronic inflammation), compared with demographically and behaviorally similar uninfected individuals. A host of biomarkers that are linked to chronic inflammation are also associated with HIV-associated non-AIDS-defining events, including cardiovascular disease, many forms of cancer, liver disease, renal disease, neurocognitive decline, and osteoporosis. Furthermore, chronic HIV infection may interact with long-term treatment toxicity and weight gain after ART initiation. These observations suggest that future biomarker-guided discovery and treatment may require attention to multiple biomarkers and, possibly, weighted indices. We are clinical trialists, epidemiologists, pragmatic trialists, and translational scientists. Together, we offer an operational definition of a biomarker and consider how biomarkers might facilitate progress along the translational pathway from therapeutic discovery to intervention trials and clinical management among people aging with or without HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.